Close Menu

equity investment

Bio-Techne said that the investment gives it a strategic foundation in diagnostics and greater access to end customers.

The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.

Pages